Ligand Pharmaceuticals Inc LGND
2 trading plans running, 33 Form 144 notices for $37.3M
10-Q, 10-K and Form 144What LGND's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Mar 7, 2025 to Sep 30, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Andrew Reardon Chief Legal Officer |
Adopted 10b5-1 plan | Sep 23, 2026 | 10-Q Oct 30, 2026 | ||
What the company wroteOn September 23, 2026, Andrew Reardon, Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. The trading arrangement is designed to remain in effect until March 15, 2027 and covers the sale of up to 10,000 shares of the Company’s common stock, together with such number of shares of the Company’s common stock issued upon settlement of certain stock awards held by Mr. Reardon, net of shares sold or withheld to satisfy applicable tax obligations. | |||||
| John Kozarich Chairman of the Board of Directors |
Adopted 10b5-1 plan | Aug 12, 2026 | 10-Q Oct 30, 2026 | ||
What the company wroteOn August 12, 2026, John Kozarich, Chairman of the Board of Directors, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934. The trading arrangement is designed to remain in effect until September 30, 2027 and covers the sale of up to 12,000 shares of the Company’s common stock. | |||||
| Andrew Reardon Chief Legal Officer |
Adopted 10b5-1 plan | Nov 24, 2025 | 10-K Feb 27, 2026 | ||
What the company wroteOn November 24, 2025, Andrew Reardon, our Chief Legal Officer, adopted a 10b5-1 trading arrangement that is designed to be in effect until September 2, 2026 with respect to the sale of up to 30,000 shares of the Company’s common stock all of which underlie stock options held by Mr. Reardon. Through the date of this report, Mr. Reardon has not sold any shares under the plan. | |||||
| Octavio Espinoza Chief Financial Officer |
Adopted 10b5-1 plan | Nov 19, 2025 | 10-K Feb 27, 2026 | ||
What the company wroteOn November 19, 2025, Octavio Espinoza, our Chief Financial Officer, adopted a 10b5-1 trading arrangement that is designed to be in effect until July 31, 2026 with respect to the sale of up to 5,130 shares of the Company’s common stock all of which underlie stock options that number of shares of the Company’s common stock issued upon settlement of certain stock awards held by Mr. Espinoza minus any shares sold or withheld to cover the applicable tax payments. Through the date of this report, Mr. Espinoza has not sold any shares under the plan. Each of the aforementioned trading arrangements is intended to satisfy the affirmative defense of Rule 10b5-1(c). | |||||
| John Kozarich Director and Chairman of the Board |
Adopted 10b5-1 plan | Mar 7, 2025 | 10-Q May 9, 2025 | ||
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 8, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 12, 2026 | KOZARICH JOHN W Director |
500 | $162K |
| Nov 12, 2026 | KOZARICH JOHN W Director |
500 | $159K |
| Nov 12, 2026 | MARTINE ZIMMERMANN Director |
2,000 | $636K |
| Nov 10, 2026 | Aryeh Jason Director |
3,000 | $960K |
| Nov 4, 2026 | Aryeh Jason Director |
282 | $90K |
| Nov 2, 2026 | Aryeh Jason Director |
700 | $222K |
| Oct 30, 2026 | JASON M ARYEH Director |
1,209 | $385K |
| Oct 30, 2026 | Aryeh Jason Director |
202 | $65K |
| Sep 10, 2026 | MARTINE ZIMMERMANN Director |
1,200 | $342K |
| Sep 3, 2026 | ANDREW REARDON Officer |
15,000 | $4.3M |
| Aug 12, 2026 | OCTAVIO ESPINOZA Officer |
31,641 | $9.1M |
| Aug 12, 2026 | Jason Haas Director |
7,138 | $2.1M |
| Jul 1, 2026 | ANDREW REARDON Officer |
10,000 | $3.2M |
| Jun 16, 2026 | STEPHEN L. SABBA Director |
2,145 | $545K |
| Jun 12, 2026 | JASON HAAS Director |
6,461 | $1.7M |
| Jun 11, 2026 | Aryeh Jason Director |
4,500 | $1.1M |
| Jun 10, 2026 | Aryeh Jason Director |
500 | $125K |
| Jun 10, 2026 | JOHN L LAMATTINA Director |
4,519 | $1.1M |
| Jun 10, 2026 | Aryeh Jason Director |
5,000 | $1.2M |
| May 13, 2026 | JOHN KOZARICH Director |
1,575 | $352K |
| May 12, 2026 | JOHN KOZARICH Director |
459 | $103K |
| May 1, 2026 | KOZARICH JOHN W Director |
467 | $107K |
| Apr 1, 2026 | KOZARICH JOHN W Director |
467 | $95K |
| Mar 23, 2026 | STEPHEN L. SABBA Director |
1,000 | $208K |
| Mar 11, 2026 | OCTAVIO ESPINOZA Officer |
3,057 | $649K |
| Mar 6, 2026 | JOHN L LAMATTINA Director |
2,161 | $434K |
| Mar 4, 2026 | ANDREW REARDON Officer |
20,000 | $4.1M |
| Mar 4, 2026 | OCTAVIO ESPINOZA Officer |
13,423 | $2.7M |
| Mar 3, 2026 | STEPHEN L. SABBA Director |
2,034 | $410K |
| Feb 2, 2026 | KOZARICH JOHN W Director |
467 | $90K |
| Jan 2, 2026 | KOZARICH JOHN W Director |
467 | $88K |
| Dec 12, 2025 | OCTAVIO ESPINOZA Officer |
1,804 | $340K |
| Dec 1, 2025 | KOZARICH JOHN W Director |
467 | $93K |
Show the other 25 notices
From the Form 144 XML filed with the SEC, since Dec 1, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LGND/export.csv") into a cell.